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It is not known how the immune system targets hepatitis C virus (HCV)-infected HLA-mismatched 
hepatocytes under immune-suppressed conditions after orthotopic liver transplantation (OLT).  In 
addition,  the relationship between the HCV-speciﬁc immune response and IL28B variants as predictors 
of HCV clearance has not been well-characterized.  We determined the IL28B polymorphisms for 57 
post-OLT HCV carriers,  and we assessed the HCV-speciﬁc immune responses by measuring the 
peripheral blood mononuclear cell-derived HCV-speciﬁc interferon-gamma (IFN-γ) response using an 
enzyme-linked immunospot assay.  At 1-3 years after OLT,  patients with no active hepatitis showed 
higher total spots on the immunospot assay.  At＞3 years after OLT,  patients with resolved HCV 
showed higher levels of core,  NS3,  NS5A,  and total spots compared to the chronic hepatitis patients.  
The IL28B major genotype in the donors correlated with higher spot counts for NS5A and NS5B pro-
teins at 1-3 years after OLT.  In the post-OLT setting,  the HCV-speciﬁc immune response could be 
strongly induced in patients with no active hepatitis with an IL28B major donor or sustained virologi-
cal response.  Strong immune responses in the patients with no active hepatitis could only be main-
tained for 3 years and diminished later.  It may be beneﬁcial to administer IFN treatment starting 3 
years after OLT,  to induce the maximum immunological eﬀect.
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epatitis C virus (HCV)-related liver cirrhosis is 
a common indication for orthotopic liver trans-
plantation (OLT).  Unfortunately,  almost all patients 
become HCV-RNA-positive after OLT,  and approx.  
25ｵ develop liver cirrhosis within a few years [1,  2].  
The pathogenesis of and the therapeutic approaches 
for recurrent hepatitis C are some of the most impor-
tant issues in liver transplantation research.
　 The main pathogenesis of HCV-related disease is 
H
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known to involve the immune reaction to virus-infected 
hepatocytes [2].  A lack of strong Th1-type helper 
T-cell responses and cytotoxic T-cell responses against 
HCV leads to chronic infection by this virus [3].  A 
strong Th1-type helper T-cell response and the cyto-
toxic T-cell response correlates with spontaneous 
recovery and interferon (IFN)-induced sustained viro-
logical response (SVR) [4].  The importance of the 
immune reaction has also been noted in post-OLT 
chronic hepatitis C (CHC) patients.
　 Several studies found that HCV-speciﬁc immune 
responses correlate with post-OLT hepatitis C pro-
gression [5,  6].  High frequencies of regulatory T 
cells (Tregs) under various clinical conditions of HCV 
carriers have been conﬁrmed in several studies.  In 
patients with severe recurrent hepatitis C,  regula-
tory-type Tr1 cells [7] or interleukin (IL)-17 might 
induce HCV-targeted hepatitis [6].  Despite the 
immune-suppressive adaptation in OLT patients,  sev-
eral immune functions could be exaggerated.  A high 
frequency of Tregs inhibiting the HCV-speciﬁc CD4＋
Th1 response,  but not the Th17 response,  was found 
in post-OLT patients with advanced ﬁbrosis [6].  Such 
dysregulation of the immune response balance must be 
included in the pathogenesis of post-OLT CHC.
　 A human genome-wide association study uncovered 
many disease-susceptible genes and drug sensitivity-
related genes [8].  In CHC patients,  an IL28B gene 
single nucleotide polymorphism (SNP) was found to be 
related to spontaneous clearance and susceptibility to 
treatment with pegylated IFN (Peg-IFN) plus ribavi-
rin [9-11].  The combination of recipient and donor 
IL28B genetic polymorphisms has been revealed to be 
important in post-OLT HCV treatment outcomes [12].
　 However,  this genetic polymorphism and the virus-
speciﬁc immune responses have not been well-charac-
terized.  An enzyme-linked immunospot (ELISPOT) 
assay is an eﬃcient technique for the enumeration of 
cells secreting antibodies or cytokines.  We hypothe-
sized that HCV-speciﬁc immune responses evaluated 
by ELISPOT assay might diﬀer between post-OLT 
HCV-positive patients and non-OLT CHC patients in 
various clinical courses.  Here we examined whether 
correlations exist among HCV-speciﬁc CD4 T-cell 
responses,  IL28B genetic polymorphism,  and the 
clinical course among post-OLT hepatitis C patients.
Materials and Methods
　 Patients. From October 1996 to January 2012,  
an OLT was performed in 280 adults at Okayama 
University Hospital.  Of the 64 patients who received 
OLT due to HCV-related end-stage liver cirrhosis,  
57 patients underwent an IL28B SNP analysis.  The 
characteristics of the study subjects are summarized 
in Table 1,  2,  and 3.  No patients showed co-infection 
with hepatitis B virus or human immunodeﬁciency 
virus.  The serotype distribution of HCV was sero-
type 1 in 85ｵ and serotype 2 in 15ｵ of the patients.  
IFN treatment was adopted for 29 patients with histo-
logically conﬁrmed chronic hepatitis (CH) and high 
levels of alanine aminotransferase (ALT).  Nine 
patients received non-pegylated IFN due to pancy-
topenia or poor general condition.  Of the 29 patients 
receiving IFN,  12 (41.4ｵ) showed SVR.
　 Of the 57 patients,  46 donors consented to undergo 
an SNP analysis.  Recurrent hepatitis C was diag-
nosed by histological analysis with no rejection and by 
ﬁndings of parenchymal or portal inﬂammation.  IFN 
treatment was adopted for the 29 patients with histo-
logically conﬁrmed CH and high levels of ALT.  
Twenty-ﬁve of the 29 IFN-adopted patientsʼ donors 
consented to undergo an SNP analysis.
　 Informed consent was obtained from each patient 
included in the study,  and the study protocol conformed 
to the ethical guidelines of the 1975 Declaration of 
Helsinki and the ethical guidelines for analytical 
research on the human genome/genes in 2001 Japan as 
reﬂected in approval by the Ethics Committee at 
Okayama University Hospital.
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Table 1　 Characteristics of the post-OLT HCV patients in the 
SNP analysis
Post-OLT HCV
N 57
Age at OLT (years) 58 (52-60)
Donor age (years) 36 (30-46)
Sex (M : F) 36 : 21
Interferon treatment (%) 29 (50%)
Pre-OLT MELD 13 (11-16)
CAI (FK/CyA) 23/34
OLT,  orthotopic liver transplantation; HCV,  hepatitis C virus; SNP,  
single nucleotide polymorphism; MELD,  model for end-stage liver 
disease; CAI,  calcineurin inhibitors; FK,  FK506; CyA,  cyclosporine 
A.
　 Characteristics of immunological assay sub-
jects. We conducted immunological assays for 27 
consecutive post-OLT HCV-positive recipients at 44 
experimental time points.  All patients showed re-
infection by HCV,  resulting in various degrees of CH.  
Patients were divided into the following groups 
according to the interval between the transplantation 
date and the experiment date and the clinical condi-
tion: 3 groups by interval: Time 1 (ｦ1 year after 
OLT,  n＝11),  Time 2 (＞1 toｦ3 years after OLT,  
n＝18),  and Time 3 (＞3 years after OLT,  n＝15);  
and 3 groups by clinical condition: the OLT-CH 
group (patients with ALT＞the upper limit of normal;  
HCV-RNA-positive; Time 1,  n＝0; Time 2,  n＝4;  
Time 3,  n＝7),  the OLT-SD group (patients with no 
active hepatitis without IFN [i.e.,  stable disease];  
HCV-RNA-positive; Time 1,  n＝11; Time 2,  n＝12;  
Time 3,  n＝5),  and the OLT-SVR group (patients 
with SVR following treatment with IFN; HCV-RNA-
negative; Time 1,  n＝0; Time 2,  n＝2; Time 3,  
n＝3).  All patients were also analyzed for IL-28B 
SNPs.  All patients were Japanese.  The general 
characteristics of the groups are summarized in Table 
2.  Patients were treated using a standard immuno-
suppressive regimen (tacrolimus or cyclospo rine A 
and/or mycophenolate mofetil with steroids).
　 As controls,  non-OLT CHC patients were included.  
These individuals were divided into 3 groups: the CH 
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Table 2　 Characteristics of post-OLT HCV patients for ELISPOT assay
Post-OLT HCV
ｦ1-year post-OLT 1-to 3-year post-OLT ＞3-year post-OLT
n 11 18 15
Age at assay (years) 55 (52-59) 61 (54-63) 62 (57-65)
Sex (M : F) 6 : 5 10 : 8 3 : 12
Clinical course of HCV (CH : SD : SVR) 0 : 11 : 0 4 : 12 : 2 7 : 5 : 3
HCV RNA (＋) 11 16 12
Interferon (%) 0 (0) 3 (16) 8 (53)
Total bilirubin (mg/dL) 0.86 (0.74-2.15) 0.98 (0.70-1.22) 0.97 (0.79-1.41)
Albumin (g/dL) 3.5 (3.1-4.3) 4.2 (3.5-4.4) 4.0 (4.0-4.4)
ALT (IU/l) 89 (48-207) 31 (17-46) 44 (22-59)
Pre-OLT MELD 12 (8-13) 13 (11-16) 12 (10-15)
CAI (FK : CyA) 4 : 7 9 : 9 5 : 10
ELISPOT,  enzyme-linked immunospot; MELD,  model for end-stage liver disease; CH,  patients with ALT＞upper limit of normal: HCV-
RNA-(＋); SD,  patients with no active hepatitis without IFN: HCV-RNA-(＋); SVR,  patients with sustained viral response to interferon:  
HCV-RNA-(－); ALT,  alanine aminotransferase; MELD,  model for end-stage liver disease; CAI,  calcineurin inhibitors; FK,  FK506; CyA,  
cyclosporine A.
Table 3　 The ELISPOT assay results of the non-OLT HCV patients
HCV total
HCV-RNA (＋)
CH
HCV-RNA (＋)
PNALT HCV-RNA (－)
n 38 20 7 11
Age at assay (years) 60 (54-71) 58 (52-63) 76 (40-78) 61 (57-74)
Sex (M : F) 22 : 16 11 : 9 2 : 5 9 : 2
HCV RNA (log copies/mL) 6.0 (0-6.5) 6.4 (6.0-6.7) 6.2 (4.7-6.7) -
Total bilirubin (mg/dL) 0.72 (0.54-0.87) 0.71 (0.54-0.82) 0.68 (0.42-1.05) 0.81 (0.53-1.24)
Albumin (g/dL) 4.2 (3.7-4.4) 4.2 (3.6-4.4) 4.1 (4.0-4.3) 4.2 (3.3-4.5)
ALT (IU/L) 30 (18-58) 53 (31-74)＊＃ 18 (18-19) 19 (13-55)
＊p＜0.05 vs. HCV-RNA (＋) PNALT; ＃p＜0.05 vs. HCV-RNA (－)
ALT,  alanine aminotransferase; CH,  patients with ALT＞upper limit of normal; PNALT,  patients with persistent normal ALT without IFN.
group (n＝20) with active CHC (ALT＞the upper 
limit of normal with HCV-RNA-positive status); the 
PNALT group (n＝7) with persistently normal ALT 
without IFN (ALT＜the upper limit of normal with 
HCV-RNA-positive status) and the RNA(－) group 
(n＝11) with HCV-RNA-negative with or without IFN.
　Laboratory tests. HCV antibody was routinely 
measured in serum using a commercially available 
chemiluminescent enzyme immunoassay (Lumipulse 
System; Fujirebio,  Tokyo,  Japan).  HCV RNA was 
measured in serum using the qualitative COBAS 
Amplicor assay (Roche,  Pleasanton,  CA,  USA).
　 Determination of the IL28B SNP mutation 
(rs8099917). To determine the genotype of IL28B 
SNP rs8099917,  genomic DNA was extracted from 
peripheral blood using a silica-membrane-based DNA 
extraction kit (Qiagen,  Tokyo,  Japan) according to the 
protocols provided by the manufacturer.  Eluted DNA 
was stored at －80℃ until analysis.  The rs8099917 
SNP was determined using TaqMan predesigned SNP 
genotyping assays in a LightCycler 480 system (Roche 
Diagnostics,  Tokyo,  Japan),  as recommended by the 
manufacturer.  The genotype was determined to be the 
major homozygous allele (TT) as a beneﬁcial genotype 
for pegylated IFN plus ribavirin treatment,  and the 
minor heterozygous/homozygous allele (TG/GG).  We 
were able to obtain the SNP genotypes of all samples 
with this system.
　 HCV recombinant proteins for ELISPOT 
assay. The HCV recombinant proteins (genotype 
1b sequence) HCV-core,  -NS3,  -NS4,  -NS5A and 
-NS5B were purchased from Mikrogen (Martinsried,  
Germany).  These proteins were used as stimulating 
antigens at 1µg/mL for ELISPOT assay.
　 IFN-γ ELISPOT assay with myeloid den-
dritic cells (DCs) and CD4-positive T cells.
Mononuclear cells were separated from peripheral 
blood by centrifugation on a Ficoll-Hypaque density 
gradient (GE Healthcare Bio-Sciences AB,  Uppsala,  
Sweden),  as described [13].  CD14-positive mono-
cytes were puriﬁed positively using microbeads 
(Miltenyi Biotec,  Belgisch Gladbach,  Germany) in 
accord with the manufacturerʼs protocol.  CD4-positive 
T cells (T4) were subsequently positively sorted in the 
same manner.  The positively selected fraction proved 
to be＞95ｵ positive for CD14 or CD4 by ﬂow cyto-
metric analysis staining with ﬂuorescein isothiocya-
nate (FITC)-conjugated anti-CD14 or CD4 antibody 
(BD Pharmingen,  San Jose,  CA,  USA).  The T4 cells 
were immediately frozen.
　 CD14-positive cells were cultured at 1×106/mL 
in RPMI-5ｵ heat-inactivated human AB serum (ICN 
Biomedicals,  Aurora,  OH,  USA; or MP Biomedicals,  
Santa Ana,  CA,  USA) supplemented with 100ng/mL 
of granulocyte macrophage colony-stimulating factor 
(GM-CSF) (kindly provided by Kirin Pharma,  Tokyo,  
Japan) and 50ng/mL of IL-4 (kindly provided by Ono 
Pharmaceuticals,  Osaka,  Japan) at 37℃ in 5ｵ CO2 
for 5 days.  Cells were conﬁrmed to be CD11c-positive 
myeloid immature DCs (iDCs).
　 Each HCV protein (1µg/mL) was pulsed to the 
iDC culture and kept still for 1 day.  An HCV protein 
unloaded buﬀer that was used for HCV protein puriﬁ-
cation was added to the iDC culture as a negative 
control.  As a positive control,  tuberculin puriﬁed 
protein derivative (PPD) (Japan BCG Laboratory,  
Tokyo) was added to the iDC culture as a recall anti-
gen at a concentration of 0.1µg/mL.  To mature DCs,  
1ng/mL of lipopolysaccharide (Sigma,  St.  Louis,  
MO,  USA) was added to the culture 1 day after HCV 
protein addition.  The same day,  mouse anti-human 
IFN-γ antibody (Mabtech,  Nacka Strand,  Sweden) 
was diluted to 5µg/mL with ELISPOT buﬀer 
(0.159ｵ Na2CO3,  0.293ｵ NaHCO3) and coated over-
night at 4℃ on a 96-well ﬁltration plate (Millipore,  
Billerica,  MA,  USA) with 100µL per well.
　 The coated plate was washed with phosphate-buﬀ-
ered saline (PBS) and blocked with 10ｵ fetal calf 
serum RPMI1640 medium for 1-2h.  Myeloid DCs 
were counted and seeded at 6×103 cells/well.  
Cryopreserved T4 cells were thawed,  counted and 
seeded at 2×105/well.  The next day,  the plate was 
washed 6 times with PBS.  Rabbit anti-IFN-γ serum 
was diluted to 1/800 with PBS and used to coat the 
wells following incubation at 37℃ for 2h.  The plate 
was washed 6 times with PBS and coated with goat 
anti-rabbit IgG-AP (Southern Biotech,  Birmingham,  
AL,  USA) diluted to 1/2000 with PBS.  After cul-
turing for 1h at 37℃,  the plate was washed 6 times 
with water,  and spots were developed with 5-bromo-
4-chloro-3-indolylphosphate p-toluidine salt and nitroblue 
tetrazolium chloride as a substrate.  Spot development 
was stopped after 10 min by washing with distilled 
water.  Spot counts were calculated using a micro-
scope.
　 If the positive control well with PPD showed no 
294 Acta Med.  Okayama　Vol.  68,  No.  5Tsuzaki et al.
spots,  we did not use the results,  in order to avoid 
assay failure.  A single assay was performed for post-
OLT patients,  and we used a duplicate assay for some 
of the control non-OLT patients because we were able 
to collect enough PBMCs from controls.
　 The spots were counted by 2 specialists (authors 
K.K.  and Y.M. ) blinded to the identities of the groups 
and then averaged.  The ﬁnal spot counts results were 
derived as the target spot count minus the spot count 
for the negative control well.  If the spot count for the 
negative control well was more than that for the tar-
get,  a value of zero spots was used.  Healthy controls 
showed less than 5 spots,  indicating that the non-spe-
ciﬁc responses were minimal.  Representative assay 
results are shown in Fig.  1.
　 Statistical analysis. To compare the mean 
values of relative indices,  we used the Kruskal-Wallis 
test with the Dunnett post-test or Studentʼs t-test on 
JMP version 9 software (SAS Institute,  Cary,  NC,  
USA).  Diﬀerences were considered signiﬁcant for 
values of p＜0.05.
Results
　 IL28B SNP analysis of post-OLT patients.
Of the 57 recipients and 46 donors enrolled in this 
study,  78ｵ and 76ｵ carried the IL28B major 
genotype,  respectively (Fig.  2A).  The combination of 
recipient and donor genotypes was 68ｵ major and 
major (MM),  15ｵ mixture of major and minor (mix),  
and 15ｵ minor and minor (mm).  The natural course 
of patients reﬂecting the IFN requisite was unaﬀected 
by SNPs (Fig.  2B).
　 Twenty-two patients ﬁnished IFN treatment and 
were followed for longer than 6 months,  with 10 
patients (45ｵ) achieving SVR.  Of the 22 patients 
who ﬁnished IFN treatment,  17 patients had serotype 
1 HCV with 11 having no viral response (NVR) and 
six achieving SVR (35ｵ).  The IL28B SNP was 
analyzed for all of the 17 serotype 1 patients,  show-
ing 72ｵ NVR and 83ｵ SVR with major genotype 
(Fig.  2C).  Seventy percent of the NVR donors car-
ried the major genotype,  whereas 100ｵ of the SVR 
donors carried the major genotype.  Although the 
recipient/donor genotype combination showed no sig-
niﬁcant association with viral response,  no patients 
with the mm combination showed SVR.
　 HCV-speciﬁ c IFN-γ ELISPOT assay for non-
OLT CHC patients. To examine the correlation 
between HCV-speciﬁc IFN-γ ELISPOT results and 
clinical conditions,  we ﬁrst evaluated the diﬀerence in 
spot counts between the HCV antibody-positive patients 
with positive HCV-RNA and those with negative 
HCV-RNA who had achieved eradication of HCV 
(Fig.  3A).  The numbers of HCV NS3- and NS4-
speciﬁc spots were higher in the HCV-RNA-negative 
patients,  resulting in higher spot counts.  A further 
analysis was conducted to determine whether hepatitis 
activity aﬀected the spot counts in the HCV-RNA-
positive patients,  by dividing the HCV-RNA-positive 
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Fig. 1　 Representative result of an ELISPOT assay.
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Fig. 2　 IL28B SNP (rs8099917) analy-
sis of post-orthotopic liver transplantation 
(OLT) patients.  Results are shown as the 
major homozygous allele M (TT) and the 
minor heterozygous/homozygous allele m 
(TG/GG).  To reveal the combination 
eﬀects of the recipient and donor geno-
types,  the recipient M and donor M 
combination is shown as “MM”,  the 
recipient m and donor m combination as 
“mm”,  and the mixture of M and m as 
“mix”.  (A) The distribution of recipient 
and donor genotypes.  (B) The distribu-
tion of recipient and donor genotypes 
according to IFN treatment requirement.  
Patients who required IFN treatment 
because of chronic hepatitis C recurrence 
were regarded as the IFN group.  Patients 
who showed no active hepatitis were 
regarded as the No IFN group.  (C) The 
distribution of recipient and donor geno-
types in HCV genotype 1-infected 
patients who ﬁnished more than 6 months 
of IFN treatment and were followed for an 
additional 6 months to determine the viral 
response.  NVR,  patients who showed 
HCV-RNA-positive results after 6 months 
from end of treatment.  SVR,  sustained 
viral responders who cleared the virus.
Fig. 3　 HCV-specific IFN-γ ELISPOT 
assay for non-OLT CHC patients.  The cor-
relation between HCV-specific IFN-γ 
ELISPOT results and clinical conditions in 
the non-OLT patients was evaluated.  (A) 
The diﬀerence in spot counts between the 
HCV antibody-positive patients with positive 
HCV-RNA and those with negative HCV-
RNA who had achieved eradication of HCV.  
(B) The HCV-RNA-positive patients were 
divided into persistent normal ALT (PNALT) 
and chronic hepatitis (CH) groups.
patients into PNALT and CH groups (Fig.  3B).  The 
PNALT group showed a slight increase in spot counts 
and no signiﬁcant diﬀerence from the CH and HCV-
RNA-negative groups.
　 HCV-speciﬁ c IFN-γ ELISPOT assay for post-
OLT CHC patients. Next,  we analyzed the 
ELISPOT data of the post-OLT CHC patients.  Since 
the eﬀects of immune-suppressive treatment are strong 
in the early period after OLT,  and because anti-HCV 
treatment would be administered as time passed,  we 
divided the post-OLT CHC patients into 3 groups 
according to time after OLT: Time 1 (T1),  ｦ1 year 
after OLT; Time 2 (T2),  ＞1 year toｦ3 years after 
OLT; and Time 3 (T3),  ＞3 years after OLT (Fig.  
4A).  The spot counts increased with time,  but no 
signiﬁcant diﬀerences were identiﬁed.
　 We divided the data into 3 groups according to the 
clinical conditions,  as (1) stable disease (SD),  reﬂect-
ing patients with no active chronic hepatitis recur-
rence although ALT or bilirubin levels might be 
higher due to rejection or biliary complications; (2) 
CH,  reﬂecting patients with chronic hepatitis; and (3) 
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Fig. 4　 HCV -speci f ic  IFN -γ 
ELISPOT assay for post-OLT CHC 
patients.  The correlation between 
HCV-speciﬁc IFN-γ ELISPOT assay 
results and post-OLT clinical condi-
tions was evaluated.  (A) Spot counts 
at diﬀerent time points after OLT.  (B) 
Spot counts under diﬀerent clinical 
conditions and time points after OLT.  
We divided the spot counts into 3 
groups according to the interval 
between the operation and the mea-
surement date and by the clinical 
condition: 3 groups by interval,  Time 
1 (＜1 year after OLT,  n＝11),  Time 
2 (ｧ1 to＜3 years after OLT,  n＝
18),  and Time 3 (ｧ3 years after OLT,  
n＝15) and 3 groups by clinical 
condit ion : the OLT -CH group 
(patients with ALT＞ the upper limit of 
normal; HCV-RNA-positive) (Time 1,  
n＝0; Time 2,  n＝4; Time 3,  n＝7),  
the OLT-SD group (patients with no 
active hepatitis without IFN; HCV-
RNA-positive) (Time 1,  n＝11; Time 
2,  n＝12; Time 3,  n＝5),  and the 
OLT-SVR group (patients with SVR 
following treatment with IFN; HCV-
RNA-negative) (Time 1,  n＝0; Time 
2,  n＝2; Time 3,  n＝4).
SVR,  reﬂecting patients who received IFN treatment 
and eradicated their HCV (Fig.  4B).  In the T2 group,  
the sum of spots was signiﬁcantly higher in the SD 
patients compared to the CH patients,  suggesting the 
signiﬁcance of an HCV-speciﬁc immune response to 
control hepatitis activity in HCV-RNA carriers.  In the 
T3 group,  the HCV core-,  NS3-,  and NS5A-speciﬁc 
immune responses were higher in the SVR patients 
compared to the CH patients.  The HCV NS3-speciﬁc 
immune response was higher even in the SD patients 
than in the CH patients.
　 HCV-speciﬁ c IFN-γ ELISPOT results and the 
IL28B genotype combination after OLT. Next,  
we analyzed the correlation between the IL28B geno-
type combination and the ELISPOT data in the post-
OLT patients.  Since the SVR condition induces a 
strong response,  post-OLT T2 patients other than the 
SVR patients were used for analysis (Fig.  5).  The 
IL28B major (M) donors showed stronger HCV NS5A- 
and NS5B-speciﬁc IFN-γ ELISPOT responses com-
pared to the minor (m) donors.
　 Clinical course and ELISPOT results after 
OLT. The temporal courses of representative 
post-OLT patients are shown in Fig.  6,  and Fig.  6A 
shows patients who received IFN treatment and 
achieved SVR.  The sum of spots increased over time 
and achieved high levels after viral eradication.  
Patients 5 and 6 received IFN,  but could not eradi-
cate the virus (Fig.  6B).  Their spot counts were very 
low.  The patients who showed no active hepatitis 
without IFN (Patients 7 and 8) achieved high spot 
numbers in 2 years,  but showed diminished levels at 5 
years post-OLT.
Discussion
　We investigated the impacts of IL28B genotype and 
HCV-speciﬁc immune responses on the clinical course 
of post-living donor OLT hepatitis C patients.  Strong 
HCV-speciﬁc IFN-γ responses were seen after viral 
eradication and remained for several years.  HCV 
carriers who had no active hepatitis also showed 
strong IFN-γ response at 1-3 years,  but not after 3 
years.  The donor IL28B major genotype patients 
showed stronger HCV speciﬁc immune responses at 
1-3 years post-OLT.  Maintaining the HCV-speciﬁc 
immune response is crucial to controlling hepatitis 
activity.
　 The pathogenesis of CHC has been thought to 
involve immune responses,  since the virus itself has no 
cytotoxic eﬀects on hepatocytes.  Previous studies 
revealed that HCV itself induces oxidative stress in 
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Fig. 5　 HCV -speci f ic  IFN -γ 
ELISPOT results and IL28B genotype 
combination in T2 patients after OLT.  
The correlation between the IL28B 
genotype combination and the 
ELISPOT data in the post-OLT 
patients was evaluated.  Post-OLT T2 
patients other than the SVR patients 
were used for this analysis.  The IL28B 
major (M) donors showed greater HCV 
NS5A- and NS5B-speciﬁc spot counts 
compared to the minor (m) donors.
hepatocytes [14-16],  resulting in worse outcomes 
[17].  However,  immune responses including IFN 
treatment are still the only way to achieve virus 
eradication.  In particular,  a strong HCV-speciﬁc 
T-cell response correlates with viral eradication [3].
　 In the present study,  a strong HCV-speciﬁc T-cell 
response was exerted in post-SVR patients even sev-
eral years after OLT.  This result is consistent with 
previous reports on non-OLT patients and post-OLT 
patients [3,  18].  HCV carriers showed weak HCV-
speciﬁc immune responses in both non-OLT and post-
OLT settings.  HCV itself has several unfavorable 
eﬀects on the human immune system.  HCV core pro-
tein blocks IFN signaling by interacting with signal 
transducer and activator of transcription protein-1 
(STAT1) [19].  HCV NS3/4A serine protease cleaves 
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Fig. 6　 Clinical course and ELISPOT data 
after OLT.  The clinical courses of represen-
tative post-OLT patients.  (A) Patients who 
received IFN treatment and achieved SVR.  
Patients 1,  2,  and 3 had IL28B MM,  and 
Patient 4 had the mix pattern of IL28B geno-
type.  Patients 5 and 6 received IFN,  but 
could not eradicate the virus.  Patients who 
showed no active hepatitis without IFN 
(OLT-SD; Patients 7 and 8) achieved high 
spot numbers at 2 years,  but showed dimin-
ished levels at 5 years post-OLT.
Cardif,  resulting in the dislocation of Cardif from 
mitochondria and the reduction of downstream IFN-β 
production [20].
　 Concerning T-cell responses,  high levels of per-
sisting viral antigen result in chronic T-cell activation 
with a sequential loss of T-cell function including 
IFN-γ production [2].  In our experiments,  from 1-3 
years after OLT,  the HCV-speciﬁc immune response 
in the SD patients was stronger than that in the CH 
patients,  but was diminished later.  This phenomenon 
suggests that a strongly maintained immune response 
in the early period could control hepatitis activity,  but 
diminishes later,  possibly due to sustained unfavor-
able eﬀects of HCV on immune function.  Introducing 
IFN treatment in this period with a strong HCV 
immune response seems likely to oﬀer an eﬀective 
protocol,  whereas rejection should be addressed using 
IFN [21].
　 The present results revealed only the CD4 T-cell 
response,  which reﬂects only part of the HCV-speciﬁc 
immune response.  Elucidation of the HCV-speciﬁc 
CD8 T-cell response by tetramer assay is important.  
However,  as previously reported,  the HCV-derived 
epitopes for a tetramer assay are mainly HLA-A2- or 
-A24-restricted and can be adapted only to patients 
possessing these HLA loci.  The number of such 
patients in the present study was too low to include 
them.  In addition,  the number of collected lympho-
cytes was too small to use them for a CD8 T-cell 
analysis.
　 To assess immune responses after OLT,  HLA 
mismatches between recipient and donor represent an 
important issue.  We used antigen-presenting cells and 
CD4 T cells from recipients to perform this assess-
ment.  However,  in the body,  HCV peptide must be 
expressed on donor hepatocytes,  and the immune 
response should attack them.  To identify these reac-
tions,  donor antigen-presenting cells must be used,  but 
the allo-reactive mixed lymphocyte response in that 
situation might be too strong to reveal the relatively 
weak anti-HCV response.  We therefore used the auto-
response system.  With this system,  we cannot reveal 
recipient T-cell and donor hepatocyte reactions,  but 
we can investigate immune reactions between recipient 
CD4 T cells and recipient-derived liver-resident anti-
gen-presenting cells such as macrophages or mono-
cytes.  Such immune reactions play signiﬁcant roles in 
the post-OLT hepatitis C situation.
　 To reveal the signiﬁcant impacts of IL-28B regard-
ing the clinical course of post-OLT HCV recurrence,  
analyses of many more patients are needed.  Even a 
previous IL28B genotyping study including 327 
recipients with 108 IFN receivers and 70ｵ of the 
corresponding donors could not ﬁnd a signiﬁcant dif-
ference between SVR and non-SVR groups [22].  
Another study regarding the natural course of HCV-
related OLT revealed that the “favorable” IL28B 
SNP could be unfavorable when present in the donor 
[23].  We assessed only 57 recipients with 46 donors 
and 29 recipients with 25 donors who received IFN 
treatment.  The natural course showed a tendency to 
be relatively less favorable with the donor SNP M 
genotype,  although no signiﬁcant diﬀerences were 
identiﬁed.  The donor IL28B genotype M might be a 
marker to discriminate SVR patients.  Here,  the 
recipient genotypes showed the same tendency as 
donor genotypes.
　 IL28B,  also called type III or lambda IFN 
(IFN-λ3),  is induced by viral infections and upregu-
lated by HCV infection [9].  IL28B interacts with a 
heterodynamic class II cytokine receptor,  IL10Rb or 
IL28Ra,  resulting in the induction of IFN-stimulated 
genes through the JAK-STAT pathway [24].  IFN-λ3 
is the product of the IL28B gene,  which has been 
found to regulate pathogens such as herpes simplex 
virus,  cytomegalovirus,  hepatitis B virus,  and HCV 
[25-27].  In our analysis,  the IL28B genotype cor-
related with the HCV-speciﬁc IFN-γ response in the 
HCV-RNA-positive post-OLT HCV patients at 1-3 
years post-OLT.  Although we must perform further 
evaluations in a greater number of patients,  HCV-
speciﬁc immune responses appear to be aﬀected by 
IL28B genotype.
　 Non-OLT HCV carriers with PNALT have been 
shown to display higher levels of regulatory T func-
tion-related FOXP3 and CTLA4 transcripts [28].  In 
the present study,  these PNALT patients showed no 
signiﬁcant diﬀerence in non-OLT CH regarding the 
HCV-speciﬁc Th1-type cytokine IFN-γ response.  This 
might be because our system showed very low 
responses in the CH and PNALT groups.  In the post-
OLT patients in the T2 group,  the patients with SD 
showed a higher sum of ELISPOTs than those with 
CH.  In the T3 group,  several HCV proteins (core,  
NS3,  NS5A) showed diﬀerences between the CH and 
SVR patients,  resulting in higher sums of spots in the 
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SVR patients.
　 Only NS3 showed a signiﬁcant diﬀerence between 
the CH and SD patients.  Follow-up data for the same 
patients also indicated that the sum of spots might be 
high at 3 years,  diminishing later.  A strong HCV-
speciﬁc IFN-γ response at 3 years might suggest the 
utility of providing treatment at that time.  We could 
not discern any reason why the post-OLT patients 
exhibited strong HCV-speciﬁc responses in SD,  while 
the non-OLT PNALT showed no such diﬀerence.  In 
the early period after living-donor liver transplanta-
tion,  regulatory T cells have been demonstrated to be 
decreased,  probably because of the use of a calcineu-
rin inhibitor [29].  The use of calcineurin inhibitors 
might be one reason for the conﬂicting results con-
cerning T-cell responses.
　 In conclusion,  strong HCV-speciﬁc immune responses 
could be achieved at 1-3 years post-OLT in donor 
IL28B-major patients.  This interval might represent 
the best timing for IFN treatment administration.  
Maintaining a strong HCV-speciﬁc immune response 
may prove beneﬁcial for the control of post-OLT 
hepatitis C activity.
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